Related Experiment Video

Updated: May 14, 2025

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.1K

miR-486-3p Suppresses Osteosarcoma Proliferation and Migration by Targeting the SPRED1-MAPK/ERK Pathway

Yu Zhang1, Yi Zhou2, Sen Zhang2

  • 1Department of Orthopaedics, The First People's Hospital of Chengdu, Chengdu, Sichuan Province, China.

Biochemical Genetics
|May 13, 2025
PubMed

Insights

MicroRNA-486-3p (miR-486-3p) is downregulated in osteosarcoma (OS) and inhibits tumor growth. Restoring miR-486-3p levels suppresses OS progression by targeting SPRED1 and inactivating the ERK1/2 pathway, offering potential therapeutic strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Regulation

Background:

  • Osteosarcoma (OS) is a primary bone cancer characterized by uncontrolled stromal cell proliferation.
  • The mitogen-activated protein kinase (MAPK) pathway, specifically ERK1/2, is crucial for OS tumor growth and metastasis.
  • MicroRNA (miRNA)-based diagnostics and therapeutics present novel avenues for OS treatment.

Purpose of the Study:

  • To investigate the regulatory role of miR-486-3p in the ERK1/2 pathway within osteosarcoma.
  • To analyze the expression patterns of miR-486-3p and its target gene SPRED1 in OS.
  • To evaluate the therapeutic potential of modulating miR-486-3p in OS.

Main Methods:

  • Analysis of miR-486-3p expression in the GEO dataset (GSE65071) and clinical OS samples.
  • In vitro studies using OS cells and in vivo studies with tumor-bearing mice to assess miR-486-3p function.
  • Bioinformatic analysis and functional assays (loss- and gain-of-function) to identify and validate miR-486-3p targets and pathways.

Main Results:

  • miR-486-3p expression is downregulated in OS tissues, correlating with advanced clinical stages.
  • Overexpression of miR-486-3p significantly inhibited OS cell proliferation, migration, and invasion.
  • miR-486-3p directly targets SPRED1, leading to the inactivation of the ERK1/2 pathway and modulation of epithelial-to-mesenchymal transition (EMT) markers.

Conclusions:

  • Downregulation of miR-486-3p contributes to OS progression by upregulating SPRED1 and activating the ERK1/2 pathway.
  • miR-486-3p acts as a tumor suppressor in osteosarcoma.
  • Targeting the miR-486-3p/SPRED1/ERK1/2 axis holds promise for novel osteosarcoma therapies.
Keywords:
ERK1/2MAPKMiR‑486‑3pOsteosarcomaSPRED1

More Related Videos

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

3.5K
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice00:07

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.2K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
2.9K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.4K